The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Objectives
Erwinia asparaginase is used as a second‐line formulation after a neutralizing hypersensitivity reaction to the first‐line formulation of asparaginase. Here, we have performed a cost‐effectiveness analysis of Erwinia asparaginase treatment.
Methods
Children with acute lymphoblastic leukemia treated according to the Dutch Childhood Oncology ALL‐10 or ALL‐11 protocol were included and...
Background
Therapeutic drug monitoring (TDM) of asparaginase is necessary to respond to variability in asparaginase activity levels, detect silent inactivation, and distinguish between real allergies and allergic‐like reactions with and without asparaginase neutralization, respectively. In this study, the costs of an individualized and fixed asparaginase dosing schedule were compared.
Procedure...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.